Filing Flows › Health Care › Impact Biomedical (IBO)
Impact Biomedical (IBO) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 7, 2026 · Impact Biomedical (IBO) Q2 2026 earnings results →
Q2 2026 Revenue down 57% year over year to $3K
Impact Biomedical made $3K in Q2 2026 (-57% Y/Y). Operating margin n/m, net loss $700K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 7, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $3K in Q2 2026, down 57% year over year and down 57% from the previous quarter.
Operating costs exceeded revenue by $702K, an operating margin of -23400.0%. Total costs fell 39% while revenue fell 57%. The quarter ended with a net loss of $700K, narrower than the previous quarter's $2.3M loss. Minority interests bore $1K of it: to shareholders the quarter was a loss of $699K.
Operating cash flow was $470K. Non-cash charges added back $284K of depreciation and amortization. Working capital and other items added $886K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 7, 2026 | $3K | -57% | n/m | −$700K | $470K |
| Q1 2026 | 10-Q | May 12, 2026 | $7K | — | n/m | −$2.3M | −$464K |
| Q4 2025 | 10-K | Mar 11, 2026 | $7K | — | n/m | $5.2M | $99K |
| Q3 2025 | 10-Q | Nov 7, 2025 | $18K | — | n/m | −$1.5M | −$613K |
| Q2 2025 | 10-Q | Aug 14, 2025 | $7K | — | n/m | −$14.4M | −$694K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Impact Biomedical
Impact Biomedical Inc. (“IBO”. “Impact”, “Impact BioMedical”, “we”, “us”, “our” or the “Company”) discovers, confirms, and patents unique science and technologies which can be developed into new offerings in human healthcare and wellness in collaboration with external partners through licensing, co-development, joint ventures, and other relationships, and currently trades on the NYSE American under ticker symbol IBO. By leveraging technology and new science with strategic partnerships, we provide advances in biopharmaceuticals, over the counter direct to consumer wellness offerings, and drug discovery for the prevention, inhibition, and treatment of neurological, oncologic, and inflammatory diseases. In addition to our existing efforts, we continually search for, and evaluate, other potential new offerings to add to our portfolio.
In its own words, from its 10-K, filed Mar 11, 2026.
Impact Biomedical against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -57% against the peers' median +7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| IBO Impact Biomedical | Q2 2026 | $3K | -57% | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Impact Biomedical 10-Q on SEC EDGAR · CIK 1834105 · Pharmaceutical Preparations
More on IBO
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results